Revolution Medicines, Inc. (RVMD)
收市後：
- Insider Monkey
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript February 26, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-1.14 EPS, expectations were $-0.86. Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]
- Zacks
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -32.56% and 87.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- InvestorPlace
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big. But not everyone is content making minor changes forever. There are still revolutionary drug stocks out there fighting to be noticed. These companies may be much smaller than their competitors, but their dre
